Anhui Fengyuan Pharmaceutical Co Ltd

Anhui Fengyuan Pharmaceutical Co Ltd has a market capitalization of CNY 2.88 billion and a price-to-earnings ratio of 28.98, indicating a relatively high valuation compared to its earnings. The company's price-to-book ratio is 1.37, suggesting that the market values the company at a slight premium to its book value. The enterprise value to EBITDA ratio is 32.02, which is a measure of the company's valuation relative to its earnings before interest, taxes, depreciation, and amortization. The company's liquidity position is assessed as medium, with a current ratio of 0.88, indicating that it has less current assets than current liabilities. The company's profitability is modest, with a return on equity of 4.72% and a return on assets of 1.96%. The gross profit margin is 18.11%, and the operating margin is 3.26%, both of which are below the industry median for pharmaceutical companies. The net profit margin is 2.58%, reflecting the company's ability to convert revenue into net income. The company's operating cash flow is CNY 119.3 million, but its free cash flow is negative at CNY -60.5 million, indicating that the company is spending more on capital expenditures than it is generating in operating cash flow. The company's capital structure is characterized by a debt-to-equity ratio of 0.55, suggesting a moderate level of leverage. The company has long-term debt of CNY 1.15 billion, which is a significant portion of its total liabilities. The company's total assets are CNY 5.06 billion, with total equity of CNY 2.1 billion. The company's capital expenditures for the period were CNY -220.6 million, indicating a significant investment in its operations. The company's revenue for the period was CNY 3.86 billion, with a gross profit of CNY 699.04 million. The company's operating income was CNY 125.89 million, and its net income was CNY 99.42 million. The company's revenue is primarily generated from its pharmaceutical products, with no specific segment breakdown provided in the available data. The company's geographic exposure is not specified in the available data, but it is likely concentrated in China given its listing on the Shenzhen Stock Exchange. The company's growth trajectory is not explicitly stated in the available data, but its revenue and net income figures suggest a stable performance. The company's capital expenditures indicate a commitment to maintaining and expanding its operations. The company's liquidity position is a concern, as it has negative net cash after subtracting total debt. The company's dilution risk is assessed as low, indicating that there is little immediate threat to shareholder value from new share issuances. Recent events and filings for the company are not detailed in the available data, but the company's financial performance and capital structure suggest that it is managing its operations in a stable manner. The company's risk assessment indicates that it has a medium liquidity risk and a low dilution risk. The company's financial position is supported by its operating cash flow, but its free cash flow is negative, which may require careful management of its capital expenditures.